The NS1 protein of the parvovirus MVM Aids in the localization of the viral genome to cellular sites of DNA damage.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
29
07
2020
accepted:
24
09
2020
revised:
28
10
2020
pubmed:
17
10
2020
medline:
26
1
2021
entrez:
16
10
2020
Statut:
epublish
Résumé
The autonomous parvovirus Minute Virus of Mice (MVM) localizes to cellular DNA damage sites to establish and sustain viral replication centers, which can be visualized by focal deposition of the essential MVM non-structural phosphoprotein NS1. How such foci are established remains unknown. Here, we show that NS1 localized to cellular sites of DNA damage independently of its ability to covalently bind the 5' end of the viral genome, or its consensus DNA binding sequence. Many of these sites were identical to those occupied by virus during infection. However, localization of the MVM genome to DNA damage sites occurred only when wild-type NS1, but not its DNA-binding mutant was expressed. Additionally, wild-type NS1, but not its DNA binding mutant, could localize a heterologous DNA molecule containing the NS1 binding sequence to DNA damage sites. These findings suggest that NS1 may function as a bridging molecule, helping the MVM genome localize to cellular DNA damage sites to facilitate ongoing virus replication.
Identifiants
pubmed: 33064772
doi: 10.1371/journal.ppat.1009002
pii: PPATHOGENS-D-20-01660
pmc: PMC7592911
doi:
Substances chimiques
DNA, Viral
0
DNA-Binding Proteins
0
NS1 protein, minute virus of mice
0
Viral Nonstructural Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009002Subventions
Organisme : NIAID NIH HHS
ID : F32 AI131468
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI148511
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI116595
Pays : United States
Déclaration de conflit d'intérêts
Matthew S. Fuller is employed by Ultragenyx Gene Therapy. There are no other competing interests to declare.
Références
PLoS Pathog. 2014 May 15;10(5):e1004117
pubmed: 24832099
Elife. 2018 Jul 20;7:
pubmed: 30028293
J Virol. 1999 Sep;73(9):7410-20
pubmed: 10438831
Virology. 2011 Feb 20;410(2):375-84
pubmed: 21193212
J Gen Virol. 1992 Jul;73 ( Pt 7):1839-43
pubmed: 1385828
J Cell Biol. 2008 Apr 21;181(2):227-40
pubmed: 18411308
Mol Cell. 2020 May 21;78(4):739-751.e8
pubmed: 32259483
J Gen Virol. 2002 Jul;83(Pt 7):1659-1664
pubmed: 12075084
Methods Mol Biol. 2014;1150:97-111
pubmed: 24743992
J Virol. 1983 Sep;47(3):600-10
pubmed: 6312084
Bio Protoc. 2019 Mar 20;9(6):
pubmed: 31032382
Chem Biol. 2010 May 28;17(5):421-33
pubmed: 20534341
Nature. 1976 Sep 9;263(5573):106-9
pubmed: 967244
PLoS Pathog. 2010 Oct 07;6(10):e1001141
pubmed: 20949077
PLoS Pathog. 2014 Jan;10(1):e1003891
pubmed: 24415942
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Virology. 2011 Mar 30;412(1):233-43
pubmed: 21295324
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5522-7
pubmed: 10792046
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):554-9
pubmed: 25540416
Cell. 2014 Dec 18;159(7):1665-80
pubmed: 25497547
Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):10912-10917
pubmed: 28973861
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70
pubmed: 21307310
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
J Virol. 1995 Mar;69(3):1652-60
pubmed: 7853501
Cell. 2017 Jul 27;170(3):507-521.e18
pubmed: 28735753
Virology. 2001 Jul 5;285(2):346-55
pubmed: 11437668
J Biol Chem. 2004 Sep 24;279(39):40723-8
pubmed: 15262976
BMC Genomics. 2019 Jul 12;20(1):579
pubmed: 31299901
Cell Rep. 2019 Sep 24;28(13):3497-3509.e4
pubmed: 31553917
J Virol. 2000 May;74(10):4807-15
pubmed: 10775619
Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):947-52
pubmed: 14732683
J Virol. 2017 Jun 26;91(14):
pubmed: 28446681
Viruses. 2017 Oct 31;9(11):
pubmed: 29088070
J Virol. 2009 Jan;83(1):117-27
pubmed: 18922873
J Cell Biol. 2008 Apr 21;181(2):213-26
pubmed: 18411307
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
J Virol. 2012 Aug;86(15):8328-32
pubmed: 22623787
Nat Cell Biol. 2015 Jan;17(1):44-56
pubmed: 25503565
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12482-7
pubmed: 17636126
Cell. 2013 Jan 31;152(3):620-32
pubmed: 23352430
Nat Genet. 2006 Nov;38(11):1278-88
pubmed: 17057718
Bioinformatics. 2009 Aug 1;25(15):1952-8
pubmed: 19505939
J Virol. 1995 Sep;69(9):5422-30
pubmed: 7636987
J Virol. 1988 Aug;62(8):2736-44
pubmed: 2969054
J Virol. 1993 Mar;67(3):1579-89
pubmed: 8437230
J Virol. 2002 Jul;76(13):6518-31
pubmed: 12050365
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
J Virol. 2014 Sep 1;88(17):10189-99
pubmed: 24965470
J Virol. 1988 Mar;62(3):851-60
pubmed: 3339715
Virology. 1992 Sep;190(1):365-77
pubmed: 1388310
J Virol. 2001 Aug;75(15):7009-17
pubmed: 11435581
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cold Spring Harb Perspect Biol. 2013 Feb 01;5(2):
pubmed: 23293137
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
J Virol. 2001 May;75(9):4394-8
pubmed: 11287588
Virology. 1998 Nov 10;251(1):123-31
pubmed: 9813208
Genes Dev. 2004 Jun 1;18(11):1305-16
pubmed: 15175262
Genome Biol. 2013;14(10):R121
pubmed: 24176123
EMBO J. 2004 Jul 7;23(13):2674-83
pubmed: 15201865
J Virol. 1990 Dec;64(12):6166-75
pubmed: 2147041
PLoS Pathog. 2014 Apr 03;10(4):e1004055
pubmed: 24699724
Bioinformatics. 2019 Nov 1;35(21):4392-4393
pubmed: 30923821